tailieunhanh - Hematologic Malignancies: Myeloproliferative Disorders - part 4

Nhiều BCR-ABL kinase đột biến miền kháng polyclonal imatinib chất ức chế tyrosine kinase (STI571) trong giai đoạn mãn tính và vụ nổ cuộc khủng hoảng dòng tủy mãn tính bệnh bạch cầu. Ung thư di động 2:117-125 Shah NP, Trần C, Lee năm tài chính, Chen P, D Norris, Sawyers CL (2004) Thay kháng imatinib với một chất ức chế kinase cuốn tiểu thuyết của ABL | References 101 Shah NP Nicoll JM Nagar B Gorre ME Paquette RL Kuriyan J Sawyers CL 2002 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib STI571 in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 117-125 Shah NP Tran C Lee FY Chen P Norris D Sawyers CL 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 399-401 Skorski T Kanakaraj P Nieborowska Skorska M Ratajczak MZ Wen SC Zon G Gewirtz AM Perussia B Calabretta B 1995 Phosphatidyl-inositol-3 kinase activity is regulated by BCR ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86 726-736 Smith KM Yacobi R Van Etten RA 2003 Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 12 27-37 Talpaz M Silver RT Druker BJ Goldman JM Gambacorti-Passerini C Guilhot F Schiffer CA Fischer T Deininger MW Lennard AL Hoch-haus A Ottmann OG Gratwohl A Baccarani M Stone R Tura S Mahon FX Fernandes-Reese S Gathmann I Capdeville R Kantar-jian HM Sawyers CL 2002 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia results of a phase 2 study. Blood 99 1928-1937 Talpaz M Rousselot P Kim D-W Guilhot F Corm S Bleickard E Zink R Rosti G Coutre S Sawyers C 2006 A phase II study of dasatinib in patients with chronic myeloid leukemia CML in myeloid blast crisis who are resistant or intolerant to imatinib first results of the CA180006 START-B study. Blood 106 16a Tauchi T Boswell HS Leibowitz D Broxmeyer HE 1994 Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 179 167-175 Tauchi T Sumi M Nakajima A Sashida G Shimamoto T Ohyashiki K 2003 BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res 9 4267-4273 Thomas J Wang L Clark RE Pirmohamed M .